Evidence map›Paper›PMID 37408004›Full record

ArticleAlzheimer's research & therapy2023

Regional cerebral tau predicts decline in everyday functioning across the Alzheimer's disease spectrum.

Mark A Dubbelman, Kayden J Mimmack, Emily H Sprague, Rebecca E Amariglio, Patrizia Vannini, Gad A Marshall, Alzheimer’s Disease Neuroimaging Initiative

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mark A DubbelmanDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. mdubbelman@bwh.harvard.edu.
Kayden J MimmackDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Emily H SpragueCenter for Alzheimer Research and Treatment, Brigham and Women's Hospital, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, Boston, MA, 02115, USA.
Rebecca E AmariglioDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Patrizia VanniniDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Gad A MarshallDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Alzheimer’s Disease Neuroimaging Initiative
Harvard University · USMassachusetts General Hospital · USBrigham and Women's Hospital · US

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Decoding neural systems underlying anosognosia for memory loss in aging and Alzheimer's diseaseR01AG061083 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI VANNINI, PATRIZIA · 2019 to 2023
$4.3M
NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

backgroundEmerging difficulty performing cognitively complex everyday tasks, or 'instrumental activities of daily living' (IADL) may be an early clinical sign of Alzheimer's disease (AD). We aimed to investigate how changes over time in everyday functioning relate to cerebral tau burden across the AD clinical spectrum.

methodsWe included 581 participants (73.9 ± 7.6 years old; 52% female) from the Alzheimer's Disease Neuroimaging Initiative who underwent tau positron emission tomography (PET) and completed at least two assessments of the Functional Activities Questionnaire (FAQ). Participants were classified as cognitively normal (n = 334) or symptomatic (n = 247). We analyzed the association between longitudinal FAQ scores and baseline tau in six temporal, parietal, and frontal brain regions in mixed-effects models. Models were run in the entire sample, as well as stratified by diagnostic group (cognitively normal or symptomatic). We additionally investigated tau-PET adjusted for, as well as interacting with, amyloid-β.

resultsGreater tau burden in several frontal, temporal, and parietal regions was associated with steeper decline over time in everyday functioning. These findings remained when adjusting for baseline global cortical amyloid-β; amyloid-β itself was only associated with change over time in FAQ scores when tau was not included in the model. When stratifying by diagnostic group, most associations between tau and everyday functioning, adjusted for amyloid-β, were present only in the symptomatic group.

conclusionsThe rate of change in everyday functioning is related to baseline tau burden in various brain regions, more strongly so than global cortical amyloid-β, specifically in cognitively symptomatic individuals. Longitudinal studies in incident dementia populations are needed to better understand functional changes in response to AD pathology across the disease.

Indexed as

Alzheimer DiseaseCognitive DysfunctionActivities of Daily LivingAgedAged, 80 and overAmyloid beta-PeptidesBrainFemaleHumansMalePositron-Emission Tomographytau ProteinsAmyloid beta-Peptidestau ProteinsAlzheimer’s diseaseAmyloidFunctionInstrumental activities of daily livingTau

Identifiers

PMID37408004
PMCPMC10320884
OpenAlexW4383263052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.